Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults

Clinical trial NCT01968551 · COMPLETED

Trial details

NCT number: NCT01968551
Sponsor: Gilead Sciences
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

HIV-1 HIV Infections Acquired Immunodeficiency Syndrome

Start date: 2013-09-03
Primary completion: 2015-07-21
Enrollment: 158

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.